Association of Northern California Oncologists

http://www.anco.org/

 

ANCO’s ASCO Highlights 2019
R

ANCO's ASCO 2019 Update On PARP Inhibitors In Ovarian Cancer: Niraparib + Bevacizumab Improves PFS In Recurrent Ovarian Cancer & Olaparib Monotherapy Extends PFS In Germline BRCA1/2-mutated Ovarian Cancer

By ANCO’s ASCO Highlights 2019 FEATURING Rebecca Brooks
By ANCO’s ASCO Highlights 2019 FEATURING Rebecca Brooks
317 views
September 12, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

23:46
AstraZeneca Oncology

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn
Gynecological
07:28
ANCO’s ASCO Highlights 2019

ANCO's ASCO 2019: Paclitaxel + Carboplatin - New Standard Regim…

Feat. R. Brooks
05:10
ANCO’s ASCO Highlights 2019

ANCO's ASCO 2019: Carboplatin-Paclitaxel Regimen For Vulnerable…

Feat. R. Brooks
09:21
ANCO’s ASCO Highlights 2019

ANCO's ASCO 2019 Update On PARP Inhibitors In Ovarian Cancer: N…

Feat. R. Brooks